Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 13;20:104. doi: 10.1186/s12915-022-01315-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — EZH2 inhibition arrests B-lymphoid cell differentiation. Total cell number of CD19+ B cells, CD14+ monocytes, and CD15+ neutrophils after 3 weeks of culturing cordblood-derived CD45highCD34highCD38midCD71-CD10- (P-NML) cells with lymphoid and neutrophil/monocyte lineage-stimulatory cytokines in the presence or absence of EPZ (EZH2 inhibitor) (A) or GSK-J4 (K27me demethylase inhibitor) (B) (N = 6). C Bar plot showing the number of clones with different contents (top panel). M = CD14+ monocytes, N= CD15+ neutrophils, B = CD19+ B cells, negative <10 CD45+ events, undefined = no detectable mature cells. Total number of cells expressing CD19+ (bottom panel). D Total number of HL60 cells in culture after 3, 6, and 9 days of treatment with ATRA, GSK-J4, or EPZ (N=3, Additional file 2: Table S2). E Percentage of viable cells in D (N=3, Additional file 2: Table S2). F Percentage of CD11b+ cells assessed by FACS after 48 and 72 h of treatment with ATRA, GSK-J4, or EPZ. H3K27me3 density at LOCKs identified in HL60 cells (N=3, Additional file 2: Table S3). G LOCKs identified in HL60 cells that overlapped with primary CB progenitor LOCKs (H) and were lost in monocytes (I) (two-sided t-test *p < 0.05, **p < 0.01 and ***p < 0.001)